Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
|Videos|June 10, 2019
Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC
Author(s)Shirish M. Gadgeel, MD
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.
Advertisement
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, spoke with Cancer Network about the results of a phase II study (
Advertisement
Related to this article
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
4
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
5